Evista will be used more to reduce the risk of breast cancer

October 2007

Evista will be used more to reduce the risk of breast cancer.

The FDA just approved this use for postmenopausal women with osteoporosis...or postmenopausal women at high risk for breast cancer.

Many prescribers already use Evista (raloxifene) as an alternative to tamoxifen to reduce breast cancer risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote